FDA approves expanded Camzyos label for Bristol Myers Squibb to treat obstructive HCM in patients weighing 30 kg or more

• FDA cleared an expanded label for Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in adults.
• Decision adds pediatric patients weighing 30 kg or more, making Camzyos the only FDA-approved oHCM therapy for children.
• Approval backed by Phase 3 SCOUT-HCM data showing a 48 mmHg greater reduction in Valsalva LVOT gradient versus placebo at week 28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202609301732BIZWIRE_USPR_____20260930_BW516104) on September 30, 2026, and is solely responsible for the information contained therein.